Fibroblast Activation Protein Inhibitors Market : Demand For Fibroblast Activation Protein (FAP) Inhibitors To Increase With The Rising Incidence Of Cancer Worldwide

The rising incidence of cancer around the world has spurred the use of fibroblast activation protein (FAP) inhibitors as they assist in preventing the proliferation of carcinogenic cells. In a report, titled “Fibroblast Activation Protein Inhibitors Market - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2016 – 2024,” Transparency Market Research (TMR) presents refined forecasts about the market’s trajectory between 2016 and 2024. The factors driving or restraining the global FAP inhibitors market are studied in detail as well.

As per the National Cancer Institute, over 1,685,210 new cases of cancer are expected to be diagnosed by the end of 2016 in the U.S. alone. The most common types of cancer affecting an increasing number of people are prostate cancer, breast cancer, rectum cancer, colorectal cancer, bladder cancer, lung and bronchus cancer, kidney and renal pelvis cancer, colon cancer, pancreatic cancer, and leukemia. Of these, the colorectal cancer has emerged as the third most common type of cancers affecting millions around the world. According to the World Cancer Research Fund International, each year approximately 1.5 million new cases of colorectal cancer are reported.

For Any Queries Get Solutions With A PDF Sample : http://bit.ly/2clSJoi

This alarming rise of cancer around the world has compelled government and international agencies to invest in the discovery of novel therapeutics and methods to treat colorectal cancer. The increasing prevalence of various cancers globally, is the prime factor fuelling the demand for anti-cancer drugs. In addition to this, the market is significantly gaining from the improvement in advanced therapeutic approaches such as radiotherapy, immunotherapy, targeted therapies, and chemotherapy. Although not much progress is made in the field of FAP inhibitors discovery for the treatment of various types of cancer, it still possesses substantial opportunities for the research and development in the near future.

Because FAP inhibitors hold huge opportunities in the treatment of cancer, various research and development programs are being conducted to determine their effective uses. Besides these, various agencies have also conducted several clinical trials to assess the efficacy of FAP inhibitors such as talabostat in the treatment of cancer. Another popular approach being implemented for the development of fibroblast activation protein inhibitor is the use of monoclonal antibodies. However, these approaches are yet to be used extensively in a clinical setting, mainly owing to lack of effective actions.

Regionally, North America, Latin America, Western Europe, Eastern Europe, the Middle East and Africa, and Asia Pacific constitute the key segments of the global FAP inhibitors market. TMR estimates the size of the market across all its regional segments in the report. The socio-economic and other factors influencing the market across all these regions are studied in detail as well.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: sales@transparencymarketresearch.com
Website: http://www.transparencymarketresearch.com/

This release was published on openPR.